Filana Therapeutics (FLNA) Receivables (2010 - 2020)
Filana Therapeutics (FLNA) posted Receivables of $86000.0 for Q3 2020, down 62.77% on a QoQ basis from $231000.0 in Q3 2011.
Powered by 
Analysis
Filana Therapeutics (FLNA) Receivables (2010 - 2020) Analysis & Trends
Filana Therapeutics has reported Receivables for 3 years, with the latest figure at $86000.0 in Q3 2020.
- On a quarterly basis, Receivables changed N/A year-over-year to $86000.0 in Q3 2020; TTM through Sep 2020 was $86000.0, a N/A change from a year earlier, with the FY2010 full-year figure at $7.1 million, changed N/A from the prior year.
- Receivables was $86000.0 for Q3 2020 at Filana Therapeutics, down from $231000.0 in the prior quarter.
- The five-year high for Receivables was $86000.0 in Q3 2020, with the low at $86000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Filana Therapeutics | 38.14 Mn | 38.14 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 86,000.00 |
| Sep 30, 2011 | 231,000.00 |
| Jun 30, 2011 | 908,000.00 |
| Dec 31, 2010 | 7.11 Mn |